Jeffrey L Evelhoch

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. ncbi request reprint Key factors in the acquisition of contrast kinetic data for oncology
    J L Evelhoch
    Cancer Biology Program, Barbara Ann Karmanos Cancer Institute, and Departments of Internal Medicine and Radiology, Wayne State University, Vaitkevicius MR Center, Detroit, Michigan 48201, USA
    J Magn Reson Imaging 10:254-9. 1999
  2. pmc Applications of magnetic resonance in model systems: cancer therapeutics
    J L Evelhoch
    Barbara Ann Karmanos Cancer Institute and Department of Internal Medicine, Wayne State University, Detroit, MI, USA
    Neoplasia 2:152-65. 2000
  3. doi request reprint Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, 4100 John R, Mail Code HW04HO, Detroit, MI 48201, USA
    Invest New Drugs 26:159-67. 2008
  4. ncbi request reprint Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126
    Jeffrey L Evelhoch
    Karmanos Cancer Institute, Wayne State University, Harper Hospital MR Center, Detroit, Michigan 48201, USA
    Clin Cancer Res 10:3650-7. 2004

Detail Information

Publications4

  1. ncbi request reprint Key factors in the acquisition of contrast kinetic data for oncology
    J L Evelhoch
    Cancer Biology Program, Barbara Ann Karmanos Cancer Institute, and Departments of Internal Medicine and Radiology, Wayne State University, Vaitkevicius MR Center, Detroit, Michigan 48201, USA
    J Magn Reson Imaging 10:254-9. 1999
    ..This review considers these factors and, when possible, makes specific recommendations for addressing them experimentally...
  2. pmc Applications of magnetic resonance in model systems: cancer therapeutics
    J L Evelhoch
    Barbara Ann Karmanos Cancer Institute and Department of Internal Medicine, Wayne State University, Detroit, MI, USA
    Neoplasia 2:152-65. 2000
    ....
  3. doi request reprint Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors
    Patricia M LoRusso
    Karmanos Cancer Institute, Wayne State University, 4100 John R, Mail Code HW04HO, Detroit, MI 48201, USA
    Invest New Drugs 26:159-67. 2008
    ..This Phase I clinical study was conducted to evaluate the dose and administration schedule of ZD6126...
  4. ncbi request reprint Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126
    Jeffrey L Evelhoch
    Karmanos Cancer Institute, Wayne State University, Harper Hospital MR Center, Detroit, Michigan 48201, USA
    Clin Cancer Res 10:3650-7. 2004
    ..The aim of the study reported here was to assess the ability of dynamic contrast enhanced magnetic resonance imaging (MRI) to measure the antivascular effects of ZD6126 in tumors...